ESTRO 36 Abstract Book

650 / 1082

S634 ESTRO 36 2017
_______________________________________________________________________________________________
liquid tissue marker (BioXmark®, Nanovi®, Copenhagen,
DK ) to define the local cavity for the purpose for defining
a boost volume or a target volume suitable for APBI.
Material and Methods
Preclinical investigations how to apply BioXMark® liquid
marker best for visualization by computer tomography
were performed. Subsequently, thirteen patients
underwent lumpectomy for limited stage breast cancer
disease and the tumor cavity was marked with the liquid
marker as well as a surgical clip. All patients were older
than 50 yrs, and all patients presented with hormone-
receptor positive disease less than 3 cm, pN0 and all were
potentially suitable for APBI. The tumor cavity was
marked immediately after resection with BioXmark® and
surgical clips. The liquid marker was placed before any
oncoplasty-manipulation was performed in three patients
analysed. A planning CT was performed 4-5 weeks after
surgery. The boost volume was defined, according to the
metal clips and the area marked by BioXmark.
Results
In preclincal studies a phantom was used to see that the
liquid marker sprayed over several square centimeters
achieved best Imaging qualities on comptuer
tomgraphy. Thus, applying a film of liqud marker over the
surface of interest was chosen for further clincal
investigations. Seven patients were analysed by the time
of submission. The tumor cavity was clearly marked for
the purpose of tumor cavity segmentation in six out
of seven cases. In one patient, the marker was not
reliabely discrimiated from the glandular tissue. The mean
volume or the tumor bed was 22,69 ml (range 8,1 - 40,96).
In respect to the metal clips placed on the thoracic wall
after lumpectomy, considerable displacement of the boost
target volume after oncoplasty was visualized.
Conclusion
Visualization of the tumor cavity can improve on the
accuracy of the target volume definition for APBI and may
allow optimizing PTV margins. Further investigation is
justified to reveal clinical utility of liquid-marker- based
target volume definition after lumpectomy.
EP-1180 Whole breast radiotherapy in Lateral
Decubitus position : efficacy and toxicity
E. Bronsart1, S. Dureau2, H. Xu1, F. Berger2, F. Campana1,
E. Costa1, A. Chilles1 , A. Fourquet1, Y. Kirova1
1 Institut Curie, Radiation therapy, Paris, France
2 Institut Curie, Biometrics, Paris, France
Purpose or Objective
To evaluate whole breast 3D conformal radiotherapy (RT)
delivered in lateral decubitus position (Isocentric Lateral
Dubitus ILD) and report the acute and the late cardiac and
pulmonary toxicity of a cohort of patients treated with
ILD.
Material and Methods
From 2006 to 2010, 832 patients with early-stated breast
cancer treated by conservative surgery underwent 3D-
conformal whole breast RT in the lateral decubitus
position at Institut Curie. All types of cup size was
included. The acute toxicity of treatement was evaluated
weekly using NCI CTC v3.0 scale, and the late toxicity was
evaluated once a year and started one year after the end
of RT. A dosimetric study was performed to analyse the
mean cardiac dose and the mean homolateral and
controlateral lung doses.
Results
median of follow up is 6.4 years, median age is 61,5 years
(min29-max90), and median body mass index is 26.3. 51%
have left breast cancer and 49% have right breast cancer.
Different type of fraction/dose were performed : 46.5%
66Gy in 33 fractions, 17.9% 50Gy in 25 fractions, 26.1% 40
or 41.6Gy in 15 or 13 fractions and 30Gy in 5 fractions.
Acute epidermitis was present in 93% with a median of
apparition of 4 weeks, and only 2,8% grade 3. In
multivariate analysis, the cup size has signicative
influence (p=0,0004) and the fractionation has a
significative influence (p=0,0001). After one year 94.1%
had no epidermitis. No cardiac or pulmonary toxicity was
reported. For normofractionation (2Gy fractions, 50 Gy on
the whole breast and 16Gy boost on the tumor bed) : Mean
dose to homolatéral lung (HL) is 1,4 Gy (min 0,63 Gy-max
3 Gy), mean dose to controlateral lung (CL) is 0,07Gy
(min0,37Gy-max1Gy) mean cardiac dose is 1,14 Gy
(min0,54 Gy – max4 Gy). In hypofractionation : for 41,6Gy
in 13 fractions schedule : mean dose to HL is 0,87Gy
(min0,38 Gy-max5 Gy), mean dose to CL is 0,03 Gy (min0,3
Gy-max3 Gy) mean cardiac dose is 0,77 Gy (min0,38 Gy-
max9 Gy). For 40 Gy en 15 fractions schedule : mean dose
to HL is 0,96 Gy (min0,38 Gy-max4 Gy), mean dose to CL
is 0,04 Gy (min0,02 Gy-max2,28 Gy) mean cardiac dose is
0,74Gy (min0,3 Gy-max1 Gy). In the 28,5Gy en 5 fractions
schedule : Mean dose to HL is 0,53Gy (min0,26Gy-
max3Gy), mean dose to CL is 0Gy (min0 Gy-max0,4 Gy)
mean cardiac dose is 0,37Gy (min0,6 Gy-max5 Gy). Median
overall survival is not reached, there is no influence of
fractionation on overall survival. Relapse-free survival is
not reached, with only 36 relapses without influence of
fractionation.
Conclusion
whole breast radiotherapy in the lateral decubitus position
provides excellent results with very low mean cardiac dose
and mean pulmonary dose. There is no cardiac or
pulmonary toxicity in this study. And it’s also very well
tolerated with very good acute toxicity profile.
EP-1181 dose to non-routinely delineated risk organs in
post left conservative surgery conformal breast RT
M. Abdelwahed1, M.A.H. Mohamed Abdelrahman Hassan2
1As-Salam International Hospital, oncology, Cairo, Egypt
2Kasr Alaini Center of Clinical Oncology & Nuclear
Medicine NEMROCK, clinicla oncology, cairo, Egypt
Purpose or Objective
This is a dosimetric study aiming at evaluation of radiation
doses to risk organs particularly (brachial plexus, coronary
artery & thyroid gland) in previously treated breast cancer
cases at Kasr Alaini Center of Clinical Oncology & Nuclear
Medicine after left Breast Conservative Surgery (BCS)
Our aim was to identify the patients' subgroups in need for
routine delineation of these risk organs to avoid toxic
doses to them.
Material and Methods
Twenty five female patients with left BCS treated with
external beam radiotherapy to the left breast and
supraclavicular region. Delineation of the coronaries was
done according to the University of Michigan Medical
Center; while the brachial plexus was delineated
according to the RTOG guidelines. Patient measures like
body mass index (BMI), mid beam cut separation, Central
lung distance, Maximum heart distance (MHD) and doses
to risk organs were documented (Heart V30 & heart Dmean,
brachial plexus Dmax , thyroid gland D mean,…)
Results
Age of the patients ranged from 35years to 70 years
(median=54years). BMI ranged from 22.1 to 47.6
(mean=34.2±6.7). MHD mean value was 2.9±1.1cm while
the heart V 30 mean value was 3.44±3.59% with heart D mean
range from 1.2 up to 9.00Gy (mean=3.92±2.02Gy). The
anterior descending coronary artery (ADCA) Dmax was
41.9±6.60Gy while the ADCA Dmean was 23.4±10.9Gy.
ADCA Dmean increased from 18.5±10.9Gy with MHD ≤3cm to
27.9±9.1Gy with MHD >3cm (ρ-value 0.030). ADCA Dmean
was also related to V30 of the heart as the ADCA Dmean
was 16.9±10.5Gy with V30 <2% while ADCA Dmean was
29.5±7.3Gy with V30 ≥2% (ρ-value=0.005).
BMI showed borderline significance on ADCA Dmax when the
BMI was <30, the ADCA Dmax was 37.3±10.0Gy while it was
43.7±43.7Gy when BMI ≥30 with a ρ-value 0.074.
None of the outcome parameters had clinical significance
related to the thyroid gland or brachial plexus, The